The next-generation CaviWipes 2.0 builds on a decades-long reputation of being trusted by clinicians with strong efficacy claims paramount during times of public health crisis. Fully qualifies for the EPA's rigorous Emerging Viral Pathogen Claim.
Features and Benefits
Proven effective against SARS-CoV-2 on hard non-porous surfaces
On EPA List Q*
Qualifies for the EPA’s Emerging Viral Pathogens claim for all virus types (enveloped, large and small n
on-enveloped viruses) to meet current and potentially future infection prevention needs
Enhanced Efficacy Claims - Effective against 60 relevant pathogens including Norovirus and Candida auris for added confidence in preventing healthcare associated infections.
Excellent Material Compatibility - Compatible with most non-porous, hard surfaces commonly used in clinical settings
Easy to use label - Makes it quick and easy to find critical information on efficacy, compatibility, and more 2-minute universal contact time for bacteria, viruses, and pathogenic fungi (Candida auris)
Kill Claims
2 Minute Efficacy Against
Non-Enveloped Viruses
Adenovirus Type 2
Echovirus Type 11
Enterovirus Type 71
Human Rotavirus
Norovirus
Adenovirus Type 5
Rhinovirus Type 1A
Pathogenic Fungi
Candida auris
Multi Drug-Resistant Bacteria
Penicillin-Resistant Streptococcus pneumoniae (PRSP)
Vancomycin-Resistant Enterococcus faecalis (VRE)
Methicillin-Resistant Staphylococcus aureus (MRSA)
Carbapenem-resistant Klebsiella pneumoniae (CRKP)
Multidrug-Resistant Acinetobacter baumannii (MRAB)
NDM-1 Enterobacter cloacae
Vancomycin-Intermediate Staphylococcus aureus (VISA)
Methicillin-Resistant Staphylococcus epidermidis